Aksys Ltd

Aksys — Corporate Update (October 2006)

29 slides from Aksys's corporate update, Oct 12, 2006

  1. Slide 1: [LOGO]

    [LOGO]

  2. Slide 2: Cautionary Statement

    Aksys, Ltd. - “Cautionary Statement” Certain of the statements I make during this presentation may constitute forward-looking statements within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations of management of Aksys a

  3. Slide 3: Aksys Investment Premise

    Aksys Investment Premise In-Center Hemodialysis (3x/week) Has Widely Recognized Clinical and Cost Underperformance Daily Home Hemodialysis is the Solution Extends Life Reduces Total Patient Cost Substantially Improves Quality of Life Early Adoption Happening Now Aksys Has Valuable Assets I.P. Delive

  4. Slide 4: Aksys Investment Premise: New Management Team and Board

    New Experienced Management Team and BoD CEO with 10 Years in Dialysis and Healthcare Turnaround Experience Veteran Board Anchored by Leading Shareholder Aksys Generation 2 Machine (G2) Will Solve Clinical and Cost Underperformance Issue Profitably Be Launched into Ripe Market Take Full Advantage of

  5. Slide 5: End Stage Renal Disease (ESRD) $15B US Market

    End Stage Renal Disease (ESRD) $15B US Market Causes of ESRD Diabetes High Blood Pressure Obesity Genetics Hemodialysis Patient’s Blood is Filtered Through Artificial Kidneys Controlled by Dialysis Machines Metabolic Toxins are Removed Via Diffusion and Excess Water Via Pressure Differential

  6. Slide 6: Global Dialysis Market

    Global 1,400,000 Patients Japan 256,000 Patients Europe 346,000 Patients 25% Rest of World 445,000 Patients 32% US 353,000 Patients 25% 18% Hemodialysis 327,000 Patients 93% Global Dialysis Market US 353,000 Patients ($15B) Peritoneal Dialysis 26,000 Patients 7% 7% Annual WW Growth (5% Annual US Gro

  7. Slide 7: Home Hemodialysis Market: Poised for a Paradigm Shift

    US Market Note: Merrill Lynch & Company Estimates; assumes $18,000 Revenue/Avg. Patients. Updated 7/27/06 Home Hemodialysis Market: Poised for a Paradigm Shift $500 Million Market 0 100 200 300 400 500 Revenue ($M) 2006 2007 2008 2009 2010 Year

  8. Slide 8: Daily Home Hemodialysis: Value Proposition

    Daily Home Hemodialysis: Value Proposition Improves Quality of Life Travel and Recovery Time Greatly Reduced Improved Sleep, Appetite, and Diet Clinically Superior to 3X/Week In-Center Treatment B/P Crashes 71% Cramps 76% Irregular heartbeat 90% Heart enlargement 29% Inflammation 42% EPO resistance

  9. Slide 9: Daily Hemodialysis Life Expectancy

    AGE 45 - 64 AGE 20 - 44 DAILY HEMODIALYSIS 3/WEEK HD DAILY HEMODIALYSIS 3/WEEK HD 5 10 15 20 25 30 35 40 45 USA POPULATION USA POPULATION YEARS *USRDS 2005 P125 and Company Data USA TRANSPLANT USA TRANSPLANT Daily Hemodialysis Life Expectancy

  10. Slide 10: Home Hemodialysis: Buying Behavior

    Home Hemodialysis: Buying Behavior Dialysis Clinics Make Decision to Offer Home Hemodialysis (separate license) Rent Device From Home Hemodialysis Supplier for Patients Doctors and Nurses Triage Patients to Determine Those That Should Be Encouraged to Try Home Hemodialysis Train Home Patients Patien

  11. Slide 11: Public Policy Changes Would Affect Buying Behavior

    Public Policy Changes Would Affect Buying Behavior Some Payers Pay For >3 Treatments Per Week Now Commercial Payers Some Fiscal Intermediaries Economic Benefit of Home Hemodialysis Total Costs Reduced by 17% at Kaiser Permanente of Southern California CMS’ Adjustment of Reimbursement Incentives Bene

  12. Slide 12: AKSYS Turnaround Strategy

    AKSYS Turnaround Strategy Focus on Developing G2 Clinically Differentiated (as with PHD) Ease of Use (as with PHD) Plus Transportable More Reliable Lower Cost “Product Development Markets” Maintaining a Few PHD Customers (Clinics) to Develop and Test G2 Minimize PHD Related Expense Facilitate Regula

  13. Slide 13: Aksys' New Leadership

    Aksys’ New Leadership Managing Director – Torrey Associates LLC Former Partner and Portfolio Manager at Croesus Capital Management and Vice President and Portfolio Manager at Putnam Investments Director Gretchen Piller CEO – Breakthrough Therapeutics, Acting CEO and Director – Access Pharmaceuticals

  14. Slide 14: Aksys' G2 Team

    Aksys’ G2 Team Howie Lewin; CEO Aksys Managed 220 Dialysis Centers as Group Vice President for DaVita Executed Turn-Around of Multiple Healthcare Businesses 10 Years Experience in Dialysis Rod Kenley; Founder, SVP Advanced Development Aksys Architect of Aksys I.P. Engineered Baxter’s “Homechoice” PD

  15. Slide 15: Aksys PHD System

    Aksys PHD System Automates time-consuming manual functions Set-up Priming Dialysis Rinsing Disinfection No chemicals; hot water Includes integrated water purification Clean-in-place blood circuit Reduces inflammatory cascade Improves outcomes Lower cost to operate Lower utilization cost allows 5-7x

  16. Slide 16: Aksys Technology: Provides Clinically Superior Outcomes

    Note: Conventional In-Center Machine Dialysis Given Daily N=2835, Aksys PHD Machine Dialysis Given Daily N =1648 Aksys Technology: Provides Clinically Superior Outcomes 0% 2% 4% 6% 8% 10% 12% 14% Hypotension P<0.001 Arrhythmia P<0.0001 Cramps P=0.016 Headache P=0.004 Nausea P=0.12 Backache P=0.002 A

  17. Slide 17: Positive Patient Feedback

    Positive Patient Feedback Patients “Feel Better” with Aksys PHD System “Since getting on the PHD, I have been skiing, learned to water ski and scuba dive, been enduro motorcycling and done my first triathlon again since starting dialysis. I am going to be the first British athlete to enter the Europ

  18. Slide 18: Aksys' Generation 2 Machine

    Aksys’ Generation 2 Machine All the Advantages of the PHD and: Smaller Transportable Lighter Quieter More Reliable Low Cost to: Manufacture Install Maintain

  19. Slide 19: G2 Will Be A Breakthrough Device

    G2 Will Be A Breakthrough Device Design and Development Partnership with DEKA Dean Kamen and Rod Kenley previously teamed-up on Baxter’s “HomeChoice” Created the APD Market and Achieved 92% Market Share Collaboration Focused on Reliable and Low Cost Design Proven Intellectual Property DEKA’s I.P. Fl

  20. Slide 20: G2 Improvements

    G2 Improvements Manufacturing 100+ hours assembly time Service In-home repairs ~510 unique parts ~350 parts contact fluid and see high temperatures Home Installation ($1000 to $2500) Plumber Required Electrician Required Professionally Installed Manufacturing 20 hours assembly time Service Depot rep

  21. Slide 21: G2's Advantages Will Stimulate Demand

    G2’s Advantages Will Stimulate Demand Cost of Consum-ables Fresenius 2008K @home NxStage System One AKSYS PHD AKSYS G2 Reliability Portability Cost to Make Cost to Clinic Ease of Use Bio-compati-bility Safety

  22. Slide 22: G2 Will Be The Cost Leader

    G2 Will Be The Cost Leader *Chart Reflects Total Cost Including Hardware, Disposables, Service and Financing 53% 29% 100% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% PHD - 2006 G2 @ Launch G2 @ Scale

  23. Slide 23: 2006-2007 Milestones

    Date Completed Non-form Prototype Integrated Prototype 9/06 Survival data published in Hemodialysis International 4Q06 Complete full cycle testing 1Q07 Data presentations at Annual Dialysis Conference 1Q07 In-form prototype completed 2Q07 Submission of data on inflammation from 2Q07 biocompatibility

  24. Slide 24: Aksys Reorganization Path to G2

    Aksys Reorganization Path to G2 $6.3m $4.75m $4.23m $5.0m $4.9m $306k $847k $1.5m $2.3m $2.0m $0 $1,000,000 $2,000,000 $3,000,000 $4,000,000 $5,000,000 $6,000,000 $7,000,000 4th Qtr 05 1st Qtr 06 2nd Qtr 06 3rd Qtr 06 4th Qtr 06 Cash Used G2 R&D

  25. Slide 25: G2 Cash Spending as % of Total

    G2 Cash Spending as % of Total 48% 63% 41% 30% 17% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Q1-06 Q2-06 Q3-06 Q4-06 2007

  26. Slide 26: 2007 Cash Requirement

    2007 Cash Requirement Total $18.5 – 19.5 million Front Loaded Professional Fees – Calendar Year End Outside programmer expense in first half Excludes Cash Cost of Financing Resolution of Delphi

  27. Slide 27: Aksys Financing Syndicate

    Aksys Financing Syndicate Funding of G2 Development and Regulatory Costs Expand Investor Base Initial Close in Q4 2006

  28. Slide 28: Clinical outcome data note

    The clinical outcome data included in this presentation is based on clinical studies and trials performed by Aksys or other third parties. Detailed information about these studies is available from the company upon request.

  29. Slide 29: Questions & Answers

    Questions & Answers www.aksys.com

Aksys — Corporate Update (October 2006) on 6ix